SAB Biotherapeutics (NASDAQ:SABS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a strong sell rating to a sell rating in a research report released on Monday morning.

A number of other research firms have also commented on SABS. Chardan Capital upped their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings downgraded shares of SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research report on Thursday. Rodman & Renshaw restated a “buy” rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Barclays initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Down 3.1%

Shares of SAB Biotherapeutics stock opened at $3.78 on Monday. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15. The firm has a market capitalization of $343.94 million, a PE ratio of -2.91 and a beta of 0.53. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $3.69 and its 200-day moving average is $3.83.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). Equities analysts anticipate that SAB Biotherapeutics will post -1.21 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. purchased a new position in SAB Biotherapeutics during the first quarter valued at approximately $29,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at $34,000. State Street Corp acquired a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at $49,000. Fifth Lane Capital LP purchased a new position in shares of SAB Biotherapeutics during the 4th quarter valued at $56,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $30,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.